- We will send in 10–14 business days.
/images/books/2815975/9780128024201.jpg)
- Publisher: Academic Press
- ISBN-10: 0128024208
- ISBN-13: 9780128024201
- Format: 15.2 x 22.9 x 2.4 cm, hardcover
- Language: English
- SAVE -10% with code: EXTRA
Translational Immunotherapy of Brain Tumors (e-book) (used book) | bookbook.eu
Reviews
Description
Translational Immunotherapy of Brain Tumors gives researchers and practitioners an up-to-date and comprehensive overview of the field. Chapters include adoptive immunotherapy, immunosuppression, CAR therapy of brain tumors, and dendritic cell therapy for brain tumors.
Very few agents have been shown to be efficacious in the treatment of malignant gliomas. Recently, there have been a number of studies demonstrating the potential success of immunotherapy for brain tumors. Immunotherapeutics are becoming the most frequent drugs to be used in cancer therapy. These new breakthroughs, now approved by the FDA, are a part of multiple phase III international trials and ongoing research in malignant glioma, meaning that the information in this cutting-edge book will be of great importance to practitioners and researchers alike.
2018 BMA Medical Book Awards Highly Commended in Oncology
EXTRA 10 % discount with code: EXTRA
The promotion ends in 17d.05:36:35
The discount code is valid when purchasing from 10 €. Discounts do not stack.
- Publisher: Academic Press
- ISBN-10: 0128024208
- ISBN-13: 9780128024201
- Format: 15.2 x 22.9 x 2.4 cm, hardcover
- Language: English English
Translational Immunotherapy of Brain Tumors gives researchers and practitioners an up-to-date and comprehensive overview of the field. Chapters include adoptive immunotherapy, immunosuppression, CAR therapy of brain tumors, and dendritic cell therapy for brain tumors.
Very few agents have been shown to be efficacious in the treatment of malignant gliomas. Recently, there have been a number of studies demonstrating the potential success of immunotherapy for brain tumors. Immunotherapeutics are becoming the most frequent drugs to be used in cancer therapy. These new breakthroughs, now approved by the FDA, are a part of multiple phase III international trials and ongoing research in malignant glioma, meaning that the information in this cutting-edge book will be of great importance to practitioners and researchers alike.
2018 BMA Medical Book Awards Highly Commended in Oncology
Reviews